Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Resources Medical Holdings CoCMHDF 90 3-Year EBITDA Growth Rate is 11.80% as of Dec. 2025, which is at its 10-year median of 11.80. GuruFocus rates CMHDF with a GF Score™ of 90/100 and a GF Value™ of $0.93. The stock has 5 warning signs investors should review. Among 523 Healthcare Providers & Services companies, China Resources Medical Holdings Co ranks better than 53.35% on this metric.
During the past 12 months, China Resources Medical Holdings Co's average EBITDA Per Share Growth Rate was -7.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 23.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of China Resources Medical Holdings Co was 41.20% per year. The lowest was -8.80% per year. And the median was 11.80% per year.
China Resources Medical Holdings Co (OTCPK:CMHDF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
China Resources Medical Holdings Co 3-Year EBITDA Growth Rate Related Terms
CMHDF vs HCA, THC, DVA: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, China Resources Medical Holdings Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Medical Holdings Co 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, China Resources Medical Holdings Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where China Resources Medical Holdings Co's 3-Year EBITDA Growth Rate falls into.
China Resources Medical Holdings Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 11.80% mean?
China Resources Medical Holdings Co (CMHDF) has a 3-Year EBITDA Growth Rate of 11.80% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for China Resources Medical Holdings Co and its competitors. This is near median its historical median of 11.80. According to the industry distribution chart, China Resources Medical Holdings Co ranks #244 out of 523 companies in the Healthcare Providers & Services industry, placing it in the top 46.7%.
Is China Resources Medical Holdings Co's 3-Year EBITDA Growth Rate too high?
China Resources Medical Holdings Co's current 3-Year EBITDA Growth Rate of 11.80% is near median its 10-year median of 11.80. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. China Resources Medical Holdings Co's value of 11.80% is 15.7% above this industry median. Based on the distribution chart, China Resources Medical Holdings Co ranks #244 out of 523 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, China Resources Medical Holdings Co has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does China Resources Medical Holdings Co's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, China Resources Medical Holdings Co ranks #244 out of 523 companies for 3-Year EBITDA Growth Rate. This puts China Resources Medical Holdings Co in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. China Resources Medical Holdings Co's value of 11.80% is 15.7% above this benchmark. While the company's 10-year median is 11.80 vs. the industry median of 10.20, China Resources Medical Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Medical Holdings Co's current 3-Year EBITDA Growth Rate of 11.80% is 15.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for China Resources Medical Holdings Co and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Medical Holdings Co's current 3-Year EBITDA Growth Rate is 11.80%, which is near median its own 10-year median of 11.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Medical Holdings Co stock overvalued right now?
China Resources Medical Holdings Co (CMHDF) has a current 3-Year EBITDA Growth Rate of 11.80%. The stock's GF Value™ is $0.93, compared to a current price of $0.58 — trading 37.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 11.80%, which is near median its 10-year median of 11.80 and 15.7% above the Healthcare Providers & Services industry median of 10.20. China Resources Medical Holdings Co's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For China Resources Medical Holdings Co (CMHDF), the current 3-Year EBITDA Growth Rate is 11.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Medical Holdings Co (CMHDF) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Medical Holdings Co stock appears to be undervalued.
The current stock price of $0.58 is trading 37.6% below its estimated GF Value™ of $0.93.
Key valuation signals for CMHDF:
3-Year EBITDA Growth Rate: 11.80% (near median its 10-year median of 11.80)
GF Value™: $0.93 vs. price of $0.58 (37.6% below fair value)
Industry Position: 15.7% above the Healthcare Providers & Services median (#244 of 523)
No single metric tells the full story. See the CMHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Medical Holdings Co Ltd is engaged in the provision of general healthcare services; provision of hospital management services, sale of pharmaceuticals, medical devices, and medical consumables, and provision of other services in the Chinese Mainland. The group has two operating segments: Hospital Business and Other Business. The Hospital Business segment includes outpatient business and inpatient business corresponding to self-owned hospitals. The Other business segment includes operation management services, supply chain services, and other ancillary services provided to participating hospitals and IOT/OT hospitals. It generates the majority of its revenue from the Hospital Business segment.
90GF Score
Get the complete analysis for CMHDF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMHDF has been successfully added to your 
